These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 14692710)

  • 1. The influence of liver metastases on the pharmacokinetics of doxorubicin---a population-based pharmacokinetic project of the CESAR-APOH.
    Müller HJ; Port RE; Grubert M; Hilger RA; Scheulen M; Mross K;
    Int J Clin Pharmacol Ther; 2003 Dec; 41(12):598-9. PubMed ID: 14692710
    [No Abstract]   [Full Text] [Related]  

  • 2. The influence of elevated liver function parameters on the pharmacokinetics of doxorubicin and epirubicin--a population based pharmacokinetic study of CESAR-APOH. Central European Society for Anticancer Drug Research. Working Group for Pharmacology in Oncology and Hematology.
    Müller HJ; Grubert M; Hilger R; Richly H; Port R; Scheulen M; Mross K;
    Int J Clin Pharmacol Ther; 2002 Dec; 40(12):575-7. PubMed ID: 12503820
    [No Abstract]   [Full Text] [Related]  

  • 3. Phase I clinical and pharmacokinetic study of S9788, a new multidrug-resistance reversal agent given alone and in combination with doxorubicin to patients with advanced solid tumors.
    Tranchand B; Catimel G; Lucas C; Sarkany M; Bastian G; Evene E; Guastalla JP; Négrier S; Rebattu P; Dumortier A; Foy M; Grossin F; Mazier B; Froudarakis M; Barbet N; Clavel M; Ardiet C
    Cancer Chemother Pharmacol; 1998; 41(4):281-91. PubMed ID: 9488597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Doxorubicin pharmacokinetics: the effect of abnormal liver biochemistry tests.
    Twelves CJ; Dobbs NA; Gillies HC; James CA; Rubens RD; Harper PG
    Cancer Chemother Pharmacol; 1998; 42(3):229-34. PubMed ID: 9685058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I and pharmacologic study of the MDR converter GF120918 in combination with doxorubicin in patients with advanced solid tumors.
    Planting AS; Sonneveld P; van der Gaast A; Sparreboom A; van der Burg ME; Luyten GP; de Leeuw K; de Boer-Dennert M; Wissel PS; Jewell RC; Paul EM; Purvis NB; Verweij J
    Cancer Chemother Pharmacol; 2005 Jan; 55(1):91-9. PubMed ID: 15565444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.
    Kontny NE; Würthwein G; Joachim B; Boddy AV; Krischke M; Fuhr U; Thompson PA; Jörger M; Schellens JH; Hempel G
    Cancer Chemother Pharmacol; 2013 Mar; 71(3):749-63. PubMed ID: 23314734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Preliminary evaluation of the pharmacokinetics and toxicity of esorubicin].
    Piazza E; Negretto E; Vago G; Pacciarini MA; Tamassia V
    G Ital Chemioter; 1985; 32(1):21-4. PubMed ID: 3830780
    [No Abstract]   [Full Text] [Related]  

  • 8. Evaluation of safety parameters and changes in serum concentration in liver transplant recipients treated with doxorubicin during the anhepatic period.
    Kobayashi S; Wada H; Hama N; Akita H; Kawamoto K; Eguchi H; Umeshita K; Doki Y; Mori M; Nagano H
    Cancer Chemother Pharmacol; 2013 Dec; 72(6):1325-33. PubMed ID: 24121480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Populational pharmacokinetics of doxorubicin applied to personalised its dosing in cancer patients].
    Escudero-Ortiz V; Ramón-López A; Duart MA; Pérez-Ruixo JJ; Valenzuela B
    Farm Hosp; 2012; 36(4):282-91. PubMed ID: 22129650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: an open-label, single-dose study.
    Mross K; Niemann B; Massing U; Drevs J; Unger C; Bhamra R; Swenson CE
    Cancer Chemother Pharmacol; 2004 Dec; 54(6):514-24. PubMed ID: 15322827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma and cellular pharmacokinetics of doxorubicin after intravenous infusion of Caelyx/Doxil in patients with hematological tumors.
    Richly H; Grubert M; Scheulen ME; Hilger RA
    Int J Clin Pharmacol Ther; 2009 Jan; 47(1):55-7. PubMed ID: 19203539
    [No Abstract]   [Full Text] [Related]  

  • 12. Dose escalation and pharmacokinetic study of AEZS-108 (AN-152), an LHRH agonist linked to doxorubicin, in women with LHRH receptor-positive tumors.
    Emons G; Kaufmann M; Gorchev G; Tsekova V; Gründker C; Günthert AR; Hanker LC; Velikova M; Sindermann H; Engel J; Schally AV
    Gynecol Oncol; 2010 Dec; 119(3):457-61. PubMed ID: 20828803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumoral efficacy and pharmacokinetic properties of pirarubicin upon hepatic intra-arterial injection in the rabbit V x 2 tumour model.
    Okada M; Kudo S; Miyazaki O; Saino T; Ekimoto H; Iguchi H; Hirano S; Kuboki H; Kadosawa H; Takeuchi T
    Br J Cancer; 1995 Mar; 71(3):518-24. PubMed ID: 7880733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lattice intrahepatic doxorubicin with and without in-flow occlusion: a pharmacokinetic study of direct liver injection.
    Averbach A; Stuart OA; Chang D; Sugarbaker PH
    Eur J Surg Oncol; 2000 Feb; 26(1):73-9. PubMed ID: 10718184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isolated liver perfusion for liver metastases: pharmacokinetic advantage?
    Ravikumar TS; Dixon K
    Surg Oncol Clin N Am; 1996 Apr; 5(2):443-9. PubMed ID: 9019363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How to Improve the Safe and Effective Use of Doxorubicin in Children with Cancer.
    van den Anker JN
    Clin Pharmacokinet; 2015 Nov; 54(11):1091-3. PubMed ID: 26123706
    [No Abstract]   [Full Text] [Related]  

  • 17. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics.
    Varela M; Real MI; Burrel M; Forner A; Sala M; Brunet M; Ayuso C; Castells L; Montañá X; Llovet JM; Bruix J
    J Hepatol; 2007 Mar; 46(3):474-81. PubMed ID: 17239480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetic modelling of doxorubicin and doxorubicinol in children with cancer: is there a relationship with cardiac troponin profiles?
    Kunarajah K; Hennig S; Norris RLG; Lobb M; Charles BG; Pinkerton R; Moore AS
    Cancer Chemother Pharmacol; 2017 Jul; 80(1):15-25. PubMed ID: 28444427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic and safety study of doxorubicin-eluting beads in a porcine model of hepatic arterial embolization.
    Lewis AL; Taylor RR; Hall B; Gonzalez MV; Willis SL; Stratford PW
    J Vasc Interv Radiol; 2006 Aug; 17(8):1335-43. PubMed ID: 16923981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic study of aldoxorubicin in patients with solid tumors.
    Mita MM; Natale RB; Wolin EM; Laabs B; Dinh H; Wieland S; Levitt DJ; Mita AC
    Invest New Drugs; 2015 Apr; 33(2):341-8. PubMed ID: 25388939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.